{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:40:41Z","timestamp":1769280041326,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaut.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T05:30:11Z","timestamp":1487050211000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-\u03b1 agents in rheumatic diseases; A systematic review and meta-analysis"],"prefix":"10.1016","volume":"79","author":[{"given":"Yuga","family":"Komaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-2558","authenticated-orcid":false,"given":"Akihiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiko","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praneeth","family":"Kudaravalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Micic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-6129","authenticated-orcid":false,"given":"Atsushi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2017.02.003_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jaut.2017.02.003_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/joim.12432","article-title":"Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody","volume":"279","author":"Isaacs","year":"2016","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.jaut.2017.02.003_bib3","series-title":"Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues","author":"Use CfMPfH","year":"2014"},{"key":"10.1016\/j.jaut.2017.02.003_bib4","series-title":"Information for Consumers (Biosimilars)","author":"Food","year":"2015"},{"key":"10.1016\/j.jaut.2017.02.003_bib5","series-title":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)","author":"Organization WH","year":"2009"},{"key":"10.1016\/j.jaut.2017.02.003_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/1744666X.2014.932690","article-title":"The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis","volume":"10","author":"Yoo","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2017.02.003_bib7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1053\/j.gastro.2009.07.049","article-title":"Th1\/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease","volume":"137","author":"Sakuraba","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2017.02.003_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2003.12.011","article-title":"Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease","volume":"126","author":"Sato","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2017.02.003_bib9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease","volume":"18","author":"Hibi","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00535-013-0807-0","article-title":"C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease","volume":"49","author":"Hibi","year":"2014","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.jaut.2017.02.003_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.7326\/M16-0428","article-title":"Bioequivalence of biosimilar tumor necrosis factor-alpha inhibitors compared with their reference biologics: a systematic review","volume":"165","author":"Chingcuanco","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2017.02.003_bib12","first-page":"15","article-title":"Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison","author":"Baji","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jaut.2017.02.003_bib13","first-page":"15","article-title":"Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis","author":"Baji","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jaut.2017.02.003_bib14","article-title":"Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: a systematic review","author":"Martelli","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jaut.2017.02.003_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.jaut.2017.02.003_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jaut.2017.02.003_bib17","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","first-page":"2011","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jaut.2017.02.003_bib18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2017.02.003_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2017.02.003_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jrsm.13","article-title":"Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity","volume":"1","author":"Pereira","year":"2010","journal-title":"Res. Synthesis Methods"},{"key":"10.1016\/j.jaut.2017.02.003_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.jaut.2017.02.003_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2017.02.003_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2014-eular.1595","article-title":"OP0012 a phase 3, randomized, double-blind, active comparator study of the efficacy and safety of Bow015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses","volume":"73","author":"Kay","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","article-title":"A\u00a0randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Choe","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2017.02.003_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2017.02.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-0981-6","article-title":"A\u00a0phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2017.02.003_bib28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/1756-185X.12711","article-title":"A\u00a0prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis","volume":"19","author":"Jani","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib29","first-page":"3946","article-title":"A\u00a0phase III, randomized, double-blind clinical study comparing SB5, an adalimumab biosimilar, with adalimumab reference product (Humira (R)) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (24-week results)","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis & Rheumatol."},{"key":"10.1016\/j.jaut.2017.02.003_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","article-title":"A\u00a0phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Emery","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2015-207613","article-title":"A\u00a0phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study","volume":"76","author":"Bae","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/1744666X.2015.1090311","volume":"11","author":"Park","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2017.02.003_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-015-0150-5","article-title":"A\u00a0randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade\u00ae) in healthy subjects","volume":"29","author":"Shin","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaut.2017.02.003_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CP202530","article-title":"Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab","volume":"54","author":"Lambert","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2017.02.003_bib35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2014-eular.2166","article-title":"FRI0264 a randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab: results of comparison with adalimumab (EU)","volume":"73","author":"Kaur","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/annrheumdis-2015-eular.1419","article-title":"FRI0110 a phase I pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in healthy subjects","volume":"74","author":"Shin","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib37","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.clinthera.2011.10.022","article-title":"Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers","volume":"33","author":"Gu","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jaut.2017.02.003_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11631860-000000000-00000","article-title":"Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel(R)): a double-blind, single-dose, crossover study in healthy volunteers","volume":"26","author":"Yi","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaut.2017.02.003_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bcp.12929","article-title":"A\u00a0randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel\u00ae) in healthy subjects","volume":"82","author":"Lee","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2017.02.003_bib40","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.02.003_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11894-015-0453-1","article-title":"Optimizing biologic agents in ulcerative colitis and Crohn's disease","volume":"17","author":"O'Toole","year":"2015","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jaut.2017.02.003_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2016-209517","article-title":"Response to:\u2018Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration\u2019 by Marshall et\u00a0al","volume":"75","author":"Emery","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2017.02.003_bib43","series-title":"EMA\/CHMP\/819219\/2015- Assessment Report -Benepali2015","first-page":"1","year":"2015"},{"key":"10.1016\/j.jaut.2017.02.003_bib44","series-title":"Use CfMPfH. Guideline on the Investigation of Bioequivalence","author":"Use CfMPfH","year":"2010"},{"key":"10.1016\/j.jaut.2017.02.003_bib45","series-title":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence","author":"Food Administration D","year":"2001"},{"key":"10.1016\/j.jaut.2017.02.003_bib46","first-page":"24","article-title":"Innovation and competition: will biosimilars succeed","volume":"9","author":"Blackstone","year":"2012","journal-title":"Biotechnol. Healthc."},{"key":"10.1016\/j.jaut.2017.02.003_bib47","series-title":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)","first-page":"2013","author":"Organization WH","year":"2009"},{"key":"10.1016\/j.jaut.2017.02.003_bib48","series-title":"US Biosimilars Guidelines: Summary and Insights","first-page":"3","author":"Chance","year":"2012"},{"key":"10.1016\/j.jaut.2017.02.003_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J.\u00a0Crohn's colitis"},{"key":"10.1016\/j.jaut.2017.02.003_bib50","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","article-title":"Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study","volume":"10","author":"Smits","year":"2016","journal-title":"J.\u00a0Crohn's colitis"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117300100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117300100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:15:48Z","timestamp":1760256948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117300100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":50,"alternative-id":["S0896841117300100"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2017.02.003","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-\u03b1 agents in rheumatic diseases; A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}